Novel glaucoma solution enters trials

Article

INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc.

INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement made by Inspire Pharmaceuticals Inc.

The Rho kinase inhibitor interferes with the actin cytoskeleton of the trabecular meshwork to lower intraocular pressure (IOP).

This placebo-controlled dose-escalating trial will appraise the compound's safety, efficacy and tolerability in early stage glaucoma or ocular hypertension.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.